• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    THE INVENTION IS IN THE FIELD OF ANTIBIOTICS. It concerns a culture of the microorganism Streptomyces Zelensis exhibiting the characteristics of the strain NRRL 11183 and capable of producing the anti-biotic CC-1065, by fermentation. IN A NUTRIENT ENVIRONMENT. </ P> <P> THIS CULTURE SHOWS AN ACTIVITY AGAINST GRAM-POSITIVE BACTERIA AND AGAINST GRAM-NEGATIVE BACTERIA. </ P>
    公开号:SU797591A3
    申请号:SU782672704
    申请日:1978-10-16
    公开日:1981-01-15
    发明作者:Джеймс Ханка Ладислав；Гленн Мартин Дейвид
    申请人:Дзе Апджон Компани (Фирма)；
    IPC主号:
    专利说明:

    (54). METHOD OF OBTAINING ANTIBIOTIC SS-1065 galactose, glucose, mannose, malto cellobiose, dextrin, soluble starch, glycerol, mannkge and inositol. It grows poorly on arabinose, sodium oxide, sodium acetate and sodium succinate. Poor - on rhamnose, sucrose, lactose, racinose, inulin, dulcite, sorbitol, salicine, phenol sodium citrate, sodium formate, sodium tar and sodium salicylate. Culture grows poorly at moderately at 18, 24 and grows well at 28, 32 and 37 ° C. At 55 ° C, no growth is observed. The proposed antibiotic is obtained by growing the body in a water-nutrient medium in submerged aerobic conditions. For surface culture, use surface cultures and flasks-bottles. The organism is grown in a nutrient medium containing a carbon source, such as an assimilating hydrocarbon, and a source of nitrogen, such as an assimilating nitrogen compound or protein substance. Preferred carbon sources include glucose, sucrose yellow sugar, glycerin, starch, corn starch, lactose, dextrin, molasses, and the like. It is preferred nym nitrogen sources include liquid from the sludge corn, yeast, avtolizovdnnye brewer's yeast with solid alloy dymi molochnymi products, soy flour, flour, cotton seed, corn mukuf solid dairy products, pancreatic product of digestion of casein, fish meal, solid alloy Dyje products by distillation , animal peptone fluids, small meat and bone debris, etc. Trace amounts of metals like zinc, magnesium, manganese; Cobalt, iron, etc., are not necessary to be added to the fermentation medium, because prior to sterilization, water containing water and impractical ingredients are used as components before sterilization. The cultivation is carried out at any temperature that ensures satisfactory growth of the microorganism, for example, in the range of about 1840 ° C, preferably about 2028 ° C. Usually, the optimal amount of antibiotic reaches within about 3-15 days. The medium usually remains alkaline during the fermentation process. The final pH depends partly on the buffer present, if any, and partly on the initial pH of the culture medium. If cultivation is carried out in large vessels or tanks, it is advisable to use a vegetative rather than spore form of the microorganism during: inoculation in order to avoid noticeable delays in the production of the antibiotic and the associated inefficient use of equipment. It is desirable to obtain a vegetative graft material in a nutrient broth culture by inoculation of this. broth culture. an aliquot of soil, liquid W-agar medium or wiring on an oblique medium. By providing such a young active vegetative graft material, it is sterile — placed in large vessels or tanks. In the isolation and purification of the antibiotic obtained by the proposed method from fermentation beer, a number of methods can be used. Extraction is carried out by extraction with solvents such as methylene chloride, acetone, butanol, ethyl acetate, and T.n.j to purify crude preparations of the antibiotic using silica gel chromatography. According to a preferred variant of the isolation process, the antibiotic is isolated from the culture medium by separating the mycelium and the undissolved solid product by conventional methods, for example, filtration or centrifugation and solvent extraction of the micelle meal and the decayed clear broth. The mycelium is extracted with acetone, and the extract is evaporated under reduced pressure to an aqueous concentrate. The aqueous concentrate is added to the filtered broth, which is then extracted three times with half the volume of methylene chloride, the United extracts are evaporated under reduced pressure, and the resulting oil is diluted with hexamole in (isomeric hexanes). The resulting slurry is cooled overnight, after which the solid product is collected, washed with sciellisole B, and dried to obtain a relatively crude preparation (yellow-brown solid product) with antibiotic CC-1065. The resulting crude antibiotic preparation is purified to obtain a substantially pure crystalline preparation of antibiotic SS-1065. The first cleaning step is the extraction of the crude preparation of the antibiotic CC-1065 with acetone. After evaporation of the acetone, the resulting residue is triturated with methanol to obtain the crystalline preparation of the antibiotic CC-1065. These crystals can be washed with cold methanol in order to increase their purity. Further purification of the antibiotic CC-1065 is carried out by chromatography on silica gel with crystallization of the active fractions. The target grade purity antibiotic CC-1065 is obtained by recrystallization of the above CC-1065 antibiotic prepared from acetone methanol. The active fractions from chromatography on silica gel are determined by thin layer chromatographs by bioautography.
    According to this method, 1 micron sample of the antibiotic sample is placed in a drop on the Baker flex silic gel IB-F silica gel and bioavtografied on the body of Bacillus subtil is (synthetic medium) or Sarcina lutea after being developed in a solution consisting of 90 h of chloroform, 10 Methanol and 0.5% concentrated ammonium hydroxide. The TLC-zone of the antibiotic CC-1065 from 1 μk or higher amounts of the crystalline sample sample can also be visualized using UV light (254 nm) as an amber light zone under obdvdchny light.
    Example. Fermentation To inoculate 500 ml Erlenmeyer kollb with 100 ml sterile medium containing wt.%: Yeast extract. O, 3 Bakto-tripton 0.5
    Dextrin0,1
    using a strain of Streptococcus 2e1ensis NRRh 11,183.
    This medium is incubated for 48 hours on a rotary vibrator like Gunp rotaru shaker at 250 rpm.
    The grafting material is used to inoculate 500 ml Erlenmeyer flasks for fermentation, with 100 ml of sterile fermentation medium containing wt.%:
    Black molasses 1 Dextrin 1
    Bakto-trypton 1, CaCOj0,5
    Sodium Chloride 0.2. The pH value is 7.2. The fermentation flasks are inoculated at a concentration of 5 MP graft material per 100ml of fermentation medium. The flasks are incubated for 120 hours at 28 ° C on a Varian type rotary vibrator at 250 rpm. The test of the antibiotic CC-1065 is completed by extracting the exhausted nutrient medium using two volumes of methylene chloride. Different amounts of methylene chloride extract (20, 10, 5, 2, and 1 µl) are applied to polygram Silica gel sheets of the type Polygram Sil - N-HR and bioavtografied on Sarcina lutea after being developed in a solvent system containing, ml:
    Methyl alcohol 10
    Chloroform90
    Ammonium hydroxide 0.5 dl. For this, 125 ml of cooled to 48 ° C agar is inoculated with Sarcina lutea ottannogo broth culture (0.5 ml / l), then pouring into plastic vessels and giving a hardener. Agar vessels are incubated at 32 ° C for 20-24 hours.
    The Sarcina lutea inoculum containing 10 cells / ml is stored as an aliquot in the gas phase of liquid nitrogen.
    Antibiotic exposure. The resulting fermentation beads from 4-fermentation processes in tanks of 10 l each are filtered through a layer of gel and ton FW 40 (diatomaceous earth). Mycelium cake extracted with acetone extract is evaporated under reduced pressure. The aqueous concentrate obtained above is added to the clear broth, then extracted three times with half the volume of methylene chloride. The NvtiO chloride extracts are evaporated under reduced pressure to an oil that is diluted with scelisolve B (1.5 L), after which the resulting slurry is cooled overnight. The solid product is then collected, washed with scelisole B, and dried to obtain a comparatively crude CC-1065 anfibiotic preparation as a tan solid. This crude preparation can be bioanalyzed by thin layer chromatography-bioautography, as described above.
    Cleaning up The preparation of the CC-1065 antibiotic preparation is extracted with acetone (400-800 ml) in order to remove some 5 large amounts of products that are insoluble in acetone. Acetone is evaporated, the residue is triturated with methanol (10 ml / mg). The slurry is cooled overnight, the obtained solid crystalline product is collected, washed with cold methanol and dried, yield 40-180 mg of the crystalline preparation of the antibiotic CC-1065. This crystalline drug is subjected to
    5 bioassay by TLC-bioavtografii on silica gel.
    Further purification is carried out. chromatography on silica gel and crystallization of the active fractions. So,
    For example, 470 mg of this crystalline solid is dissolved in 940 ml of acetone and evaporated onto 10 ml of Geduran TMS160 silica gel.
    The powder obtained is chromatographed on 100 ml of silica gel, eluting.
    5 with solvent consisting of 80 hours of chloroform, 20 hours of methanol, and 4. ammonium hydroxide. 20 fractions (20 ml each) are collected and evaporated to dryness. The fractions are then bioassayed by TLC-bioautography. Fractions 6-19 are placed in a container and triturated with methanol, yielding 218 mg of high-quality crystalline antibiotic CC-1065. Target degree
    5 purity can be achieved by recrystallization from acetone-methanol, yielding 167 g (77%) of mostly pure CC-1065 antibiotic crystals.
    The molecular weight of antibiotic CC-1065 is approximately 700, elemental analysis C 61.06; H 4.92, N 13 D7.
    UV absorption spectrum. The solution of the antibiotic SS-1065V. Dioxane shows a strong terminal absorption with the shoulders at 230. nm (ability
    00) and 258 nm (, 10 and a maximum at 364 nm (, 10).
    IR absorption spectrum. The antibiotic CC-1bb5 shows the characteristic IR spectrum of absorption in a mineral-based paste in the wavelength range of 3800-600 (see
    Peaks are observed in the following ranges of ox, 2960, 2920, 2850, 1465, and 1377, in part they depend on the aliphatic C – H vibrations of the mineral oil.
    Solubility. The antibiotic CC-1065 is soluble in solvents such as dimethyl sulfoxide (dmsf dimethylformamide, acetone, methylene chloride, ethyl acetate, dioxane, and chloroform.
     The c-NMR spectrum of the CC-1065 antibiotic at 20 MHz was found on a Varlan CFT-20 spectrometer in a solution (about 1.0m71 about 75 mg / mp) of a sample of the CC-1065 antibiotic in deuterodimethylsulfoxide. The spectrum is calibrated against the center line d6 of DMSO, labeled 39/6 H / MN1 (parts per million in terms of tetramethylsilane taken as O h / ml. Frequencies are recorded down from tetramethylsilane.
    The proton-magneto resonance spectrum (n-NMR of the antibiotic CC-1065 at 100 MHz is observed on a spectrometer of the Vartan XL 100-15 type in solution (about 0.5 MP, about 150 mg / ml of the sample-sample of the antibiotic CC-1065 in
    deuterodimethylsulfoxide (d6 DMSO). The spectrum is calibrated against internal tetramethylsilane, the frequencies are recorded in h / MJiH. down from tetramethylsilane
    Antimicrobial spectrum of the antibiotic SS-1065. The antibiotic CC-1065 acts against various gram-positive and gram-negative bacteria and fungi, as can be seen from the table.
    The experiments were carried out as follows.
    The minimum inhibitory concentration (mic) is determined by standard bactericidal methods using two-fold diluted antibiotic solutions in Brain Heart broth.
    Grafted organisms — cultures of test organisms obtained overnight were diluted so that the final population contained approximately 10 cells / ml. The tubes are incubated for 42 hours at 28-37 ° C. The MIC is determined by transferring O, 1 ml of broth from those tubes that do not show development in 10 ml of antibiotic-free broth, tubes that do not show culture growth for 24 hours are considered as containing bactericidal concentrations. Mushroom broth contains,%:
    0.5

    3.0 Dextrose Yeast
    0.7 extract
    Gram-positive bacteria Staphylococcus aureus UC 76 Staphylococcus aureus UC 552 Staphilococcus i aureus UC 70 Staphylococcus aureus UC 3665 Baci1lus sHbtilis UC 564 Streptococcus pyogenes UC 6055
    Gram-negative bacteria Escherichia col i UC 57
    Proteus vulgaris UC 93
    Pseubomonas aerugJnosa UC 95 Pseubomonas mildenbergii UC 3029
    Salmonella gallinarum UC 265
    0,0015
    0,003
    0,0015
    0,003
    0.025
    0.0008
    0.012
    0.012
    0,003
    0.32
    0.08
    0.08 0.3
    2.5
    Klebsiella pneumoniae UC 57 Salmonella schottmue11eri UC 126 Salmonella pullorum UC 267
    Fung i g
    Candida albicans UC 1392 Saccharomyces cerenisiae UC 1337 Saccharomyces pastorianus UC 1342 PeniciIlium oxalicum UC 1268 The antibiotic CC-1065 also has an effect against tumor cells L 1210, which are developed in culture (in vitro). In vivo mice, the antibiotic CC-1065 also inhibits leukemia L1210, leukemia P 388 and melanoma B 16. The antibiotic CC-1065 acts against gram-positive bacteria, for example against Proteus vulga g is, and thus can be used as a preservative Means in order to inhibit the property of this bacterium that causes spoilage of oil (vegetable. It is also useful in washing solutions in the field of sanitation. Since the antibiotic CC-1065 has an effect against Bacillus subtilis, it can be used to treat reproduction sites ovogo gypsy moth for the purpose of Warning: any or minimize infections.
    Table continuation .. "
    0.8 0.3 0.08
    权利要求:
    Claims (1)
    [1]
    0.3 0.04 0.3 0.2 caused, as is known, by this bacterium. The proposed method allows to obtain a new antibiotic, which will be used in the national household. The invention The method of obtaining an antibiotic, notably that Streptomyces zelensis 11,183 is grown in a nutrient medium containing carbon and nitrogen sources, under aerobic conditions, separates the mycelium from the culture fluid, then the mycelium is extracted with acetone, the resulting extract is concentrated, combined about the separated culture fluid and the resulting mixture is repeatedly extracted with methylene chloride.
    类似技术:
    公开号 | 公开日 | 专利标题
    SU797591A3|1981-01-15|Method of preparing cc-1065 antibiotic
    US3595955A|1971-07-27|Geldanamycin and process for producing same
    KR940000759B1|1994-01-29|Novel glycopeptide antibiotics
    US4539203A|1985-09-03|CL-1577D And CL-1577E antibiotic/antitumor compounds, their production and use
    US4056615A|1977-11-01|Lucknomycin and process for producing same
    US4144329A|1979-03-13|Antitumor antibiotics MA 144-M1 and MA 144-M2
    US4814449A|1989-03-21|Substance 4181-2
    US4954641A|1990-09-04|Novel antitumor antibiotic substance and a method for production thereof
    US4248863A|1981-02-03|Antibiotics saframycins A, B, C, D and E and process for producing the same
    US4332902A|1982-06-01|Antibiotic substance
    US4335108A|1982-06-15|Paulomycin A and B and preparation thereof
    US3359165A|1967-12-19|Antibiotic lomondomycin and method of production
    FR1465395A|1967-01-13|New compound, decoyinine and its manufacturing process
    US5117052A|1992-05-26|Physiologically active substances, benastatins a and b, and production and use thereof
    US4105658A|1978-08-08|Neothramycin antibiotics
    US4100171A|1978-07-11|Antibiotic X-14547
    AU655853B2|1995-01-12|Antibacterial substance BE-24566B
    US4230692A|1980-10-28|Ravidomycin and process of preparation
    US4588822A|1986-05-13|Physiologically active substances SS 12538, their preparation and a novel microorganism producing same
    CA2145204A1|1994-04-28|Antibiotic agents
    JP2764759B2|1998-06-11|Novel substance BT-38 substance, method for producing the same and antifungal agent containing the same as an active ingredient
    US5112858A|1992-05-12|Antibiotic, aranorosin, a microbiological process for the preparation thereof, and the use thereof as a pharmaceutical
    FR2476128A1|1981-08-21|MICROBIOLOGICAL PROCESS FOR THE PRODUCTION OF NARASIN AND CROPS CONTAINING THE PRODUCING MICROORGANISM STREPTOMYCES LYDICUS DEBOER AND AL-
    JP3055973B2|2000-06-26|Antibiotic aldecarmycin and its production method, and its derivative and its production method
    US4206129A|1980-06-03|Antibiotic SM-173B
    同族专利:
    公开号 | 公开日
    DE2841361A1|1979-04-19|
    JPS5464695A|1979-05-24|
    FR2461001B1|1983-02-04|
    CH643564A5|1984-06-15|
    FR2461001A1|1981-01-30|
    FR2405956B1|1983-03-11|
    FR2405956A1|1979-05-11|
    GB2008088A|1979-05-31|
    NL7809639A|1979-04-19|
    IT7828063D0|1978-09-25|
    US4169888A|1979-10-02|
    GB2008088B|1982-06-09|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US5475092A|1992-03-25|1995-12-12|Immunogen Inc.|Cell binding agent conjugates of analogues and derivatives of CC-1065|GB923938A|1960-02-08|1963-04-18|Takeda Chemical Industries Ltd|Rufomycin|
    US3819834A|1970-08-07|1974-06-25|Meiji Seika Kaisha|Espinomycin antibiotics and methods of preparing same|US4313935A|1979-03-05|1982-02-02|Fujisawa Pharmaceutical Co., Ltd.|Antibiotic FR-900129 substance, a process for the preparation thereof and pharmaceutical compositions containing the same|
    US4301248A|1979-12-21|1981-11-17|Bristol-Myers Company|Fermentation process for making rachelmycin|
    US4413132A|1980-11-18|1983-11-01|The Upjohn Company|Antibiotic CC-1065 indoline intermediates|
    IT1143242B|1980-11-18|1986-10-22|Upjohn Co|1,2,8, BA-CICLOPROPA-BENZODIPIRROL-4-ONE ANTIBATTE RICHLY ACTIVE AND RELATED METHOD OF PREPARATION|
    US4431820A|1980-11-18|1984-02-14|The Upjohn Company|6-Methoxy indoline acetate and its 5-nitro and 5-amino derivatives|
    US4496492A|1980-11-18|1985-01-29|The Upjohn Company|Substituted phenylalkyl compounds|
    US4423229A|1980-11-18|1983-12-27|The Upjohn Company|Composition of matter and process|
    US4423230A|1980-11-18|1983-12-27|The Upjohn Company|Preparation of an intermediate for N--1,2,8,8a-cyclopropa[c][1,2-b:-4,3-b']dipyrol-4-one|
    US4400518A|1980-11-18|1983-08-23|The Upjohn Company|Composition of matter and process|
    US4423228A|1980-11-18|1983-12-27|The Upjohn Company|Process for preparing N--1,2,8,8a-cyclopropa[c]benzo[1,2-b:4,3-b']dipyrrol-4-one|
    US4912227A|1984-02-21|1990-03-27|The Upjohn Company|1,2,8,8A-tetrahydrocyclopropapyrrolo-indol-4--ones and related compounds|
    US4978757A|1984-02-21|1990-12-18|The Upjohn Company|1,2,8,8a-tetrahydrocyclopropapyrrolo [3,2-e)]-indol-4-ones and related compounds|
    US4590280A|1985-03-15|1986-05-20|The Upjohn Company|Preparing indoline derivatives|
    EP0271581B1|1986-04-17|1993-01-13|Kyowa Hakko Kogyo Co., Ltd.|Novel compounds dc-88a and dc-89a1 and process for their preparation|
    JP2642165B2|1988-07-22|1997-08-20|協和醗酵工業株式会社|Novel DC-89 compound and method for producing the same|
    US5084468A|1988-08-11|1992-01-28|Kyowa Hakko Kogyo Co., Ltd.|Dc-88a derivatives|
    JP3380237B2|1988-09-12|2003-02-24|ファルマシア・アンド・アップジョン・カンパニー|Novel CC-1065 analogs with two CPI subunits|
    US5008271A|1988-10-21|1991-04-16|Kyowa Hakko Kogyo Co., Ltd.|DC-88A derivatives|
    JP2598116B2|1988-12-28|1997-04-09|協和醗酵工業株式会社|New substance DC113|
    JP2510335B2|1989-07-03|1996-06-26|協和醗酵工業株式会社|DC-88A derivative|
    US5187186A|1989-07-03|1993-02-16|Kyowa Hakko Kogyo Co., Ltd.|Pyrroloindole derivatives|
    WO1991016324A1|1990-04-25|1991-10-31|The Upjohn Company|Novel cc-1065 analogs|
    US5214065A|1990-06-11|1993-05-25|Kyowa Hakko Kogyo Co., Ltd.|Dc-89 derivatives|
    US5248692A|1990-06-11|1993-09-28|Kyowa Hakko Kogyo Co., Ltd.|DC-89 derivatives as anti-tumor agents|
    US5258383A|1991-06-28|1993-11-02|Kyowa Hakko Kogyo Co., Ltd.|DC-89 derivatives|
    US5248691A|1992-09-03|1993-09-28|Eli Lilly And Company|Furanoindolines|
    US5786138A|1993-01-29|1998-07-28|Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College|Hyperstabilizing antisense nucleic acid binding agents|
    US5801155A|1995-04-03|1998-09-01|Epoch Pharmaceuticals, Inc.|Covalently linked oligonucleotide minor grove binder conjugates|
    US20100056762A1|2001-05-11|2010-03-04|Old Lloyd J|Specific binding proteins and uses thereof|
    AU2002311919B8|2001-05-11|2007-03-22|Ludwig Institute For Cancer Research Ltd|Specific binding proteins and uses thereof|
    CN1463270A|2001-05-31|2003-12-24|梅达莱克斯公司|Disulfide prodrugs and linkers and stablizers useful therefore|
    US20030180766A1|2002-01-24|2003-09-25|Ecopia Biosciences, Inc.|Method, system and knowledge repository for identifying a secondary metabolite from a microorganism|
    US7691962B2|2004-05-19|2010-04-06|Medarex, Inc.|Chemical linkers and conjugates thereof|
    CA2564076C|2004-05-19|2014-02-18|Medarex, Inc.|Chemical linkers and conjugates thereof|
    US7714016B2|2005-04-08|2010-05-11|Medarex, Inc.|Cytotoxic compounds and conjugates with cleavable substrates|
    US20060045877A1|2004-08-30|2006-03-02|Goldmakher Viktor S|Immunoconjugates targeting syndecan-1 expressing cells and use thereof|
    AU2006294554B2|2005-09-26|2013-03-21|E. R. Squibb & Sons, L.L.C.|Antibody-drug conjugates and methods of use|
    BRPI0619331A2|2005-10-26|2011-09-27|Medarex Inc|method for making a compound to prepare a cbi cc-1065 analog, method for making a cbi cc-1065 analog and compound|
    WO2007059404A2|2005-11-10|2007-05-24|Medarex, Inc.|Duocarmycin derivatives as novel cytotoxic compounds and conjugates|
    TWI412367B|2006-12-28|2013-10-21|Medarex Llc|Chemical linkers and cleavable substrates and conjugates thereof|
    CA2676244C|2007-01-25|2017-01-17|Kwok-Kin Wong|Use of anti-egfr antibodies in treatment of egfr mutant mediated disease|
    EP2121667B1|2007-02-21|2016-06-08|E. R. Squibb & Sons, L.L.C.|Chemical linkers with single amino acids and conjugates thereof|
    MX2009009782A|2007-03-15|2010-09-10|Ludwig Inst Cancer Res|Treatment method using egfr antibodies and src inhibitors and related formulations.|
    CN101896503B|2007-08-14|2018-05-22|路德维格癌症研究所有限公司|The monoclonal antibody 175 and its derivative and purposes of targeting EGF receptor|
    WO2009080831A1|2007-12-26|2009-07-02|Biotest Ag|Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates|
    RU2486203C2|2007-12-26|2013-06-27|Биотест Аг|Method for improving targeted action of cd138 expressing tumour cells and agents to this effect|
    KR20100097753A|2007-12-26|2010-09-03|바이오테스트 아게|Immunoconjugates targeting cd138 and uses thereof|
    AU2008339910B2|2007-12-26|2014-01-09|Biotest Ag|Agents targeting CD138 and uses thereof|
    US9493578B2|2009-09-02|2016-11-15|Xencor, Inc.|Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens|
    EP3828205A1|2010-10-01|2021-06-02|Oxford BioTherapeutics Ltd|Anti-ror1 antibodies|
    JOP20210044A1|2010-12-30|2017-06-16|Takeda Pharmaceuticals Co|Anti-cd38 antibodies|
    WO2013022855A1|2011-08-05|2013-02-14|Xencor, Inc.|Antibodies with modified isoelectric points and immunofiltering|
    US10851178B2|2011-10-10|2020-12-01|Xencor, Inc.|Heterodimeric human IgG1 polypeptides with isoelectric point modifications|
    KR20140100571A|2011-12-08|2014-08-14|바이오테스트 아게|Uses of immunoconjugates targeting cd138|
    AU2012395148B2|2012-11-24|2016-10-27|Hangzhou Dac Biotech Co., Ltd.|Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules|
    US10131710B2|2013-01-14|2018-11-20|Xencor, Inc.|Optimized antibody variable regions|
    US10858417B2|2013-03-15|2020-12-08|Xencor, Inc.|Heterodimeric proteins|
    SI2943511T1|2013-01-14|2020-01-31|Xencor, Inc.|Novel heterodimeric proteins|
    US9701759B2|2013-01-14|2017-07-11|Xencor, Inc.|Heterodimeric proteins|
    US10487155B2|2013-01-14|2019-11-26|Xencor, Inc.|Heterodimeric proteins|
    CA2902739A1|2013-03-15|2014-09-18|Xencor, Inc.|Heterodimeric proteins|
    US11053316B2|2013-01-14|2021-07-06|Xencor, Inc.|Optimized antibody variable regions|
    WO2014113510A1|2013-01-15|2014-07-24|Xencor, Inc.|Rapid clearance of antigen complexes using novel antibodies|
    US10968276B2|2013-03-12|2021-04-06|Xencor, Inc.|Optimized anti-CD3 variable regions|
    US10519242B2|2013-03-15|2019-12-31|Xencor, Inc.|Targeting regulatory T cells with heterodimeric proteins|
    US10106624B2|2013-03-15|2018-10-23|Xencor, Inc.|Heterodimeric proteins|
    US9605084B2|2013-03-15|2017-03-28|Xencor, Inc.|Heterodimeric proteins|
    CA3093606A1|2013-03-15|2014-09-18|Xencor, Inc.|Heterodimeric proteins for induction of t cells|
    CA2926324A1|2013-10-11|2015-04-16|Jonathan Alexander Terrett|Conjugated antibodies against ly75 for the treatment of cancer|
    AU2014384434B2|2014-02-28|2016-11-03|Hangzhou Dac Biotech Co., Ltd|Charged linkers and their uses for conjugation|
    TN2017000532A1|2014-03-28|2019-04-12|Xencor Inc|Bispecific antibodies that bind to cd38 and cd3.|
    US20160060360A1|2014-07-24|2016-03-03|Xencor, Inc.|Rapid clearance of antigen complexes using novel antibodies|
    KR20170084327A|2014-11-26|2017-07-19|젠코어 인코포레이티드|Heterodimeric antibodies that bind cd3 and cd38|
    EA201791139A1|2014-11-26|2018-04-30|Ксенкор, Инк.|HETERODIMERNYE ANTIBODIES THAT BIND CD3 AND TUMOR ANTIGENS|
    US10259887B2|2014-11-26|2019-04-16|Xencor, Inc.|Heterodimeric antibodies that bind CD3 and tumor antigens|
    WO2016105450A2|2014-12-22|2016-06-30|Xencor, Inc.|Trispecific antibodies|
    US10227411B2|2015-03-05|2019-03-12|Xencor, Inc.|Modulation of T cells with bispecific antibodies and FC fusions|
    US9839687B2|2015-07-15|2017-12-12|Suzhou M-Conj Biotech Co., Ltd.|Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule|
    CA3007030A1|2015-12-07|2017-06-15|Xencor, Inc.|Heterodimeric antibodies that bind cd3 and psma|
    MX2018015592A|2016-06-14|2019-04-24|Xencor Inc|Bispecific checkpoint inhibitor antibodies.|
    US10793632B2|2016-08-30|2020-10-06|Xencor, Inc.|Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors|
    CN109715663A|2016-06-28|2019-05-03|Xencor股份有限公司|In conjunction with the heterodimeric antibody of somatostatin receptor 2|
    MA46533A|2016-10-14|2019-08-21|Xencor Inc|BISPECIFIC HETERODIMERAL FUSION PROTEINS CONTAINING FC IL -15 / IL -15 R LPHA FUSION PROTEINS AND PD -1 ANTIBODY FRAGMENTS|
    NZ752394A|2016-11-14|2021-07-30|Hangzhou Dac Biotech Co Ltd|Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers|
    CN111132733A|2017-06-30|2020-05-08|Xencor股份有限公司|Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15R α and an antigen binding domain|
    US10981992B2|2017-11-08|2021-04-20|Xencor, Inc.|Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors|
    CN112272675A|2018-02-21|2021-01-26|细胞基因公司|BCMA binding antibodies and uses thereof|
    EP3773911A2|2018-04-04|2021-02-17|Xencor, Inc.|Heterodimeric antibodies that bind fibroblast activation protein|
    EP3817770A2|2018-07-02|2021-05-12|Amgen Inc.|Anti-steap1 antigen-binding protein|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    US05/842,914|US4169888A|1977-10-17|1977-10-17|Composition of matter and process|
    [返回顶部]